Navigation Links
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows 55% Clinical Benefit in Patients With Trastuzumab-Refractory Metastatic Breast Cancer
Date:12/17/2007

Five of 20 Evaluable Patients Had Confirmed Partial Responses (25%);

Updated Data Presented at San Antonio Breast Cancer Symposium

HAYWARD, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that its Hsp90 inhibitor, tanespimycin, demonstrated meaningful antitumor activity and tolerability in a Phase 2 trial in patients with HER2-positive metastatic breast cancer, when administered in combination with trastuzumab (Herceptin(R)) in patients whose disease progressed following treatment with trastuzumab immediately prior to entering the trial. Of 20 evaluable patients, 11 patients benefited from activity, yielding an overall clinical benefit incidence of 55%, including 5 patients with confirmed partial responses, 2 patients with minor responses and 4 patients with extended stable disease. Common toxicities were mainly mild to moderate and included fatigue and gastrointestinal symptoms. Data from the Phase 2 trial were presented at the 2007 San Antonio Breast Cancer Symposium on Sunday, December 16, 2007, in a poster titled, "Tanespimycin (an Hsp90 Inhibitor) and Trastuzumab is an Active Combination in Patients (Pts) with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer (MBC): Phase 2 Trial," by Shanu Modi, M.D., of Memorial Sloan-Kettering Cancer Center.

"Tanespimycin is clearly active in patients who are refractory to trastuzumab and whose disease progressed prior to entering the study," said Clifford A. Hudis, M.D., Chief, Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, and senior author on the poster. "The tolerability of tanespimycin combined with the ability to generate meaningful and durable responses,
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NexGenix Pharmaceuticals Enters into Exclusive World-wide License to Develop Novel Hsp90 Inhibitors
2. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
3. 3 strikes, youre out? Refiling of Amendment to Change Constitution to Criminalize Stem Cell Cures Shows Trouble with Anti-Cures Cause
4. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
5. International Survey Shows People Over Forty Ignore Risk of Blindness
6. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
7. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
8. Video shows buckyballs form by shrink wrapping
9. National Survey Shows Most Women Are Not Satisfied With Their Progesterone Treatment
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... second contract from the U.S. Environmental Protection Agency ... company’s expertise in developmental toxicity models, including tests ... on neuron formation and the formation of connections ... function. Inhibition of neurodifferentiation and synapse formation by ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
(Date:7/29/2014)... 2014   Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, and Mayo Medical Laboratories (MML), ... the United States , have announced ... applications. "We have great appreciation for Mayo ... we welcome the opportunity to partner with the organization,s ...
(Date:7/29/2014)... has created a new way of manufacturing microstructured ... made by self-assembly of carbon nanotubes, could exhibit ... mechanical stiffness and strength, or the ability to ... have demonstrated that mechanical forces can be used ... and that we can independently control the ...
Breaking Biology Technology:U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4A new way to make microstructured surfaces 2
... Neb., March 18 Transgenomic Inc. (OTC Bulletin Board: TBIO) announces the following Webcast: , , ... Conference ... 5:00 p.m. Eastern, Where: http://www.transgenomic.com/events.asp?id=6 , ... on to the web at the, ...
... Pharmaceutical Inc. (Nasdaq: BMRN ) announced today ... BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the ... (MPS IVA), or Morquio A Syndrome, has been accepted ... Agency (MHRA). BioMarin expects to initiate a Phase 1/2 ...
... BALTIMORE, March 18 Champions Biotechnology, Inc. (OTC Bulletin ... advanced preclinical platforms and tumor specific data to enhance ... for the third fiscal quarter ended January 31, 2009. ... available in the Company,s Form 10-Q at www.championsbiotechnology.com ...
Cached Biology Technology:Reminder - Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 2Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 3Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 4Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 5Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results 6
(Date:7/30/2014)... a paper published online today in the journal ... researchers Evan Kodra and Auroop Ganguly found that while ... variability in temperature extremes. For instance, while each year,s ... averages will also tend to fall within a wider ... are currently being observed. This means that even as ...
(Date:7/29/2014)... climate warms and sea ice retreats, the North is ... increasingly open water which is predicted to extend across ... century. Storms thus have the potential to create Arctic ... and unpredictable element to the region. , A University of ... the middle of the Arctic Ocean, and detected house-sized ...
(Date:7/29/2014)... July 29, 2014 Research and Markets ... Business Intelligence (BI) Market 2014-2018" report to their ... The term BI refers to applications and ... or analyzing information about a company,s operations. BI help ... their business; for example, metrics on sales, production, and ...
Breaking Biology News(10 mins):Big data confirms climate extremes are here to stay 2Huge waves measured for first time in Arctic Ocean 2Huge waves measured for first time in Arctic Ocean 3Global SaaS-based Business Intelligence (BI) Market 2014-2018 2
... than their unaffected siblings to have higher levels of ... The hormone, leptin, may contribute to the known higher ... syndrome. A research team from The Childrens Hospital ... Medicine published their study online today in the Journal ...
... October 26, 2007 A new study ... predators and parasites, for mixed mating, a reproductive ... through both self- and cross-fertilization. The findings highlight ... Mating systems are a complex set of traits ...
... Hurricane Katrina on soil quality and agriculture? How can soil ... can biofuels help make America energy independent? These topics and ... Annual Meetings of the American Society of Agronomy (ASA), Crop ... America (SSSA) Nov. 4-8, 2007 at the Ernest N. Morial ...
Cached Biology News:Obesity-related hormone is higher in children with Down syndrome 2Predators and parasites may increase evolutionary stability 2Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings 2
Ca2+ Channel Ca gamma 2 Purified Anti-Mouse, Anti-Rat, Anti-Human clone Polyclonal, Isotype Rabbit Ig, 50 µl Consult technical datasheet for details....
Rabbit polyclonal antibody to NCOA2 [Agarose Immobilized]...
Monocarboxylate (lactate) transporter 2...
Mouse Anti-Human Kallikrein 2 (Hk2)...
Biology Products: